NeOnc Charting New Nasal Route to Treating Brain Cancer

DENVER, Sept. 21, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – NeOnc Technologies Holdings’ (NASDAQ: NTHI) NEO100 deserves attention; not just because its Phase 2a study has suddenly solved brain cancer, but because it is testing a different answer to one of the field’s oldest problems.

The disease is aggressive. Patients may have already undergone surgery, radiation and temozolomide. Once the tumor returns, treatment options narrow, and the central problem is not simply finding another molecule that can kill cancer cells. It is getting an effective amount of that molecule to the right place without creating unacceptable toxicity elsewhere.